Compare Aveanna Healthcare Holdings, Inc. with Similar Stocks
Dashboard
1
With a growth in Net Sales of 6.51%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 11 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 135.22 MM
- NET PROFIT(HY) Higher at USD 239.28 MM
- ROCE(HY) Highest at 373.77%
2
With ROE of 135.06%, it has a very attractive valuation with a 7.04 Price to Book Value
3
Consistent Returns over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
USD 1,368 Million (Small Cap)
5.00
NA
0.00%
6.65
135.06%
7.04
Revenue and Profits:
Net Sales:
648 Million
(Quarterly Results - Mar 2026)
Net Profit:
42 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
28.1%
0%
28.1%
6 Months
-2.64%
0%
-2.64%
1 Year
74.49%
0%
74.49%
2 Years
260.85%
0%
260.85%
3 Years
358.38%
0%
358.38%
4 Years
222.43%
0%
222.43%
5 Years
-32.91%
0%
-32.91%
Aveanna Healthcare Holdings, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
92.81%
EBIT Growth (5y)
52.55%
EBIT to Interest (avg)
1.37
Debt to EBITDA (avg)
9.28
Net Debt to Equity (avg)
-13.90
Sales to Capital Employed (avg)
1.51
Tax Ratio
60.41%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
98.47%
ROCE (avg)
8.81%
ROE (avg)
2.71%
Valuation key factors
Factor
Value
P/E Ratio
5
Industry P/E
Price to Book Value
7.04
EV to EBIT
9.95
EV to EBITDA
9.00
EV to Capital Employed
1.79
EV to Sales
1.09
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
17.98%
ROE (Latest)
135.06%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 49 Schemes (9.42%)
Foreign Institutions
Held by 71 Foreign Institutions (3.35%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
647.90
662.50
-2.20%
Operating Profit (PBDIT) excl Other Income
83.60
84.50
-1.07%
Interest
29.20
32.60
-10.43%
Exceptional Items
-7.30
-12.10
39.67%
Consolidate Net Profit
41.70
178.80
-76.68%
Operating Profit Margin (Excl OI)
117.20%
116.60%
0.06%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -2.20% vs 6.53% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -76.68% vs 1,168.09% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,433.20
2,024.50
20.19%
Operating Profit (PBDIT) excl Other Income
295.80
182.00
62.53%
Interest
140.10
156.60
-10.54%
Exceptional Items
-46.60
-26.30
-77.19%
Consolidate Net Profit
225.00
-10.90
2,164.22%
Operating Profit Margin (Excl OI)
110.00%
74.50%
3.55%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 20.19% vs 6.82% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 2,164.22% vs 91.90% in Dec 2024
About Aveanna Healthcare Holdings, Inc. 
Aveanna Healthcare Holdings, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






